Abstract: Peptides which consist of or comprise the tetrameric peptide structural unit: Xaa-Xaa-Xaa-Xaa in which Xaa at position 1 represents Glu or Asp, Xaa at position 2 represents any amino acid, Xaa at position 3 represents any amino acid and Xaa at position 4 represents Glu or Asp, each of the meanings of Xaa being independent, and peptides which consist of or comprise the sequence PYSSTA, particularly when in multimeric form, mimic the beneficial trophic and neuritogenic effects of FGF but lack the undesirable mitogenic effects. They are useful for the treatment of conditions for which FGF has been proposed, including treatment of neurodegenerative diseases, ischaemia, wound healing and stimulation of angiogenesis in cardiac muscle.

Abstract: Recombinational cloning is provided by the use of nucleic acids, vectors and methods, in vitro and in vivo, for moving or exchanging segments of DNA molecules using engineered recombination sites and recombination proteins to provide chimeric DNA molecules that have the desired characteristic(s) and/or DNA segment(s).

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: Mouse asporin protein and nucleic acid sequences are disclosed. The protein contains a unique aspartic acid region near the N-terminus. The central domain contains ten leucine rich repeats. Sequences consistent with other class I small leucine rich repeat proteoglycans (SLRP) are also observed. Methods of use for the protein include regulating the complement system, inhibiting fibrosis formation, regulating the growth of endothelial cells and angiogenesis, regulating or inhibiting the growth of cancer cells, and regulating the functions of neuromuscular junctions.

Abstract: This invention relates to therapeutic and diagnostic methods and compositions based on Jagged/Notch proteins and nucleic acids, and on their role in the signaling pathway relating to endothelial cell migration and/or differentiation. In addition, this invention provides a substantially purified Jagged protein, as well as a substantially purified nucleic acid or segment thereof encoding Jagged protein, or a functionally equivalent derivative, or allelic or species variant thereof. Further, this invention provides a substantially purified soluble Jagged protein and a substantially purified nucleic acid encoding same as well as a recombinant cell comprising a nucleic acid encoding a soluble Jagged protein. Soluble Jagged provides further therapeutic and diagnostic methods relating to diseases, disorders, and conditions involving Jagged/Notch signaling including, inter alia, angiogenesis, differentiation, and control of gene expression.

Abstract: We have successfully sequenced and cloned the gene expressing the Major Surface Protein 5 (MSP5) of A. phagocytophilum. The recombinant MSP5 (rMSP5) protein has been tested using sera from humans and dogs infected with A. phacytophilum. The polypeptide has been found to be immunogenic and useful as a diagnostic test antigen. The polypeptide antigen of the subject invention can provide the basis of a diagnostic assay that would allow the rapid, in-house, laboratory diagnosis of infection with A. phagocytophilum using a sample (e.g., serum, plasma, or whole blood) from an infected human or animal. Additionally, the subject invention provides methods of detecting the presence of A. phagocytophilum in biological or environmental samples utilizing antibodies provided by the subject invention.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: Isolated nucleic acid sequences encoding mammalian MDM2 binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein are provided.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.

Abstract: The present invention is directed to a novel polypeptides having sequence similarity to to a receptor with an immunoglobulin-like domain and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: Disclosed are fluorescent compositions and methods for detecting and/or characterizing enzymes and various uses thereof.

Abstract: The present invention relates to an azo compound represented by the following formula (1): wherein A denotes a phenyl group having 1 to 3 substituents such as sulfonic acid group, amino group, lower alkyl groups and lower alkoxyl groups, or a naphthyl group, B denotes hydrogen atom, sulfonic acid group, a lower alkyl group, a lower alkoxyl group or the like, each of R1 to R4 independently denotes hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxyl group or the like, D denotes —NHCO—, —N?N— or —NH—, E denotes hydrogen atom, a lower alkyl group or a phenyl group having 1 to 3 substituents such as hydroxyl group and amino group, n denotes 0 or 1, and m denotes 0 or 1, or a salt thereof, or a copper complex compound of either of them, which is used for a polarizing plate having excellent polarization performance and durability and furthermore little color leakage in visible light range.

Abstract: An asparagine-linked ?2,3-oligosaccharide having undeca- to hepta-saccharides, an asparagine-linked ?2,6-oligosaccharide having undeca- to hepta-saccharides and containing fluorine and an asparagine-linked oligosaccharide derivative containing at least one fucose in N-acetylglucosamine on the nonreducing terminal side of an asparagine-linked oligosaccharide wherein the asparagine has amino group protected with a lipophilic protective group, and a process for producing these compounds.

Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies B7 family member B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic, diagnostic and research purposes are also provided.

Abstract: Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

Abstract: The present invention provides nucleic acid sequences encoding a modified leukotoxin protein, wherein the modification comprises the removal of nucleic acid sequences encoding amino acids within hydrophobic transmembrane domains of full length leukotoxin protein, preferably from Mannheimia haemolytica. The modified leukotoxin proteins are useful in vaccine compositions effective against Mannheimia haemolytica in animals.

Abstract: The invention provides metRS2 polypeptides and polynucleotides encoding metRS2 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are preferred methods for utilizing metRS2 polypeptides and polynucleotides as diagnostic reagents and in diagnostic assays to screen for microbial infections in organisms and infections in materials.

Abstract: Polyol polyesters useful as nondigestible fat substitutes are prepared by improved heterogeneous interesterification processes between fatty acid esters of easily removable alcohol and polyol characterized by having one or more improvements such as using low levels of soap emulsifying agent, catalyst, and/or excess fatty acid ester; reducing the size of the polyol by mechanical means; removing extraneous particulate material during the reaction; using low temperature and/or high pressure and compensating by increasing the mass transfer area; and/or using backmixing in the initial stage(s) and plug-flow conditions in the final stage(s).

Abstract: The present invention relates to an economic synthetic method of 2-deoxy-L-ribose with easy reaction, separation and purification. The present invention consists of four (4) steps including protection, activation of 3- and 4-OH groups, inversion and deprotection steps. In respect to the cost for equipment, reagent and operation, by the present invention, 2-deoxy-L-ribose can be produced more economically because the invention uses 2-deoxy-L-ribose which is abundant in nature and easily synthesized from D-glucose and adopt simple and yielding process.

Abstract: A compound having the formula I wherein the O—(CH2)n—N(R1,R2) substituent on the phenyl ring can be in meta or para position; n is 2-4 Re and ?Re are OH, optionally independently etherified or esterified; R1 and R2 are independently (1C-4C)alkyl, (2C-4C)alkenyl, hydroxy(2C-4C)alkyl, (1C-3C)alkoxy(2C-4C)alkyl, aryl or aryl(1C-2C)alkyl; or R1 and R2 together with the nitrogen form an aromatic or non-aromatic heterocyclic ring structure, optionally mono- or poly-substituted with (1C-4C)alkyl, (2C-4C)alkenyl, hydroxy(1C-2C)alkyl, (1C-2C)alkoxy(1C-3C)alkyl or aryl. These compounds can be used for estrogen receptor ? selective medical treatments.

Abstract: A 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound of the formula (3): [R is a hydrocarbyl group], is prepared by the steps of: (I) reacting an isobutyrylacetate ester with 4-fluorobenzaldehyde and urea in the presence of a protonic compound and a metal salt; (II) oxidizing the reaction product of the step (I); (III) reacting the oxidation product of the step (II) with an organic sulfonyl halide or an organic sulfonyl anhydride; and (IV) reacting the reaction product of the step (III) with N-methyl-N-methanesulfonamide.

Abstract: A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. These compounds can be useful as factor Xa inhibitors.

Abstract: The present invention relates to methods for making racemic 2-(7-chloro -1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7 -chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone.

Abstract: Mixed bis-imine pyridine ligands of formula (I), wherein Z1, which is different from Z2, is an optionally substituted aryl group; and Z2 comprises an optionally substituted heterohydrocarbyl moiety, or an optionally substituted aryl group in combination with a metal, said optionally substituted aryl group being ?-co-ordinated to the metal; mixed bis-imine pyridine complexes comprising a ligand of formula (I); mixed ionic bis-imine pyridine complexes comprising a ligand of formula (I); and processes for the production of alpha olefins from ethylene, using said complexes.

Abstract: Methods of synthesizing nicotine analogs and derivatives are described. The methods are particularly useful for the regioselective production of enantiomerically pure nicotine anlogs having substituents at the C4 position. Intermediates useful for the synthesis of such compounds are also described.

Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

Abstract: Novel phosphonium salts of benzotraizoles, which are highly reactive coupling agents, and are particularly useful in peptide synthesis, are disclosed. Further disclosed is a process of preparing the novel phosphonium salts and methods utilizing same for preparing peptides.

Abstract: 1-Methyl-2,4,5-Trinitroimidazole is synthesized starting from 4-nitroimidazole using stepwise nitration method and further methylation using Dimethylsulphate. It is relatively insensitive to impact and its thermal stability is excellent. The calculated detonation properties indicate that its performance is about 30% better than TATB. It can be prepared easily, with reasonable yield, starting from commercially available Imidazole. Results from impact sensitivity, friction sensitivity, time-to-explosion temperature and vacuum stability tests indicate that it is less sensitive than both RDX and HMX. The good oxygen balance and measured heat of formation data of this material indicate that its propellant performance should be good.

Abstract: Disclosed are cyclic imino oligomers and polymers comprised of subunits of the formula: Also disclosed are combinatorial libraries and arrays of the cyclic imino compounds.

Abstract: A benzenesulfonate salt of (2S,4S)-2-cyano-4-fluoro-1-[(2-hydroxy-1,1-dimethyl)ethylamino]acetylpyrrolidine that has an excellent DPPIV inhibition activity as well as physical properties (e.g., stability) required for pharmaceutical preparations. The present invention allows easy obtaining of the compound in high-purity uniform crystal form with excellent solid-state stability.

Abstract: Biphenylcarboxamide compounds of formula (I) methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes.

Abstract: A class of photo-caged and cell permeable fluorescent molecules having high uncaging cross sections, robust fluorescence enhancement, and flexible chemistry for bioconjugation. Some of the photo-caged fluorescent molecules are derived from 6-chloro-7-hydroxy-coumarin 3-carboxamide. The fluorescent molecules are useful for cellular imaging applications and particularly for tracing the molecular transfer between cellular gap junctions. The fluorescent molecules also have an emission wavelength that spectrally complements with the emission wavelength of other fluorophores, enabling simultaneous multi-color imaging.

Abstract: The present invention relates to a process for preparing tetrahydropyran-4-ol which comprises the steps of (A) a cyclization step of preparing tetrahydropyranyl-4-formate represented by the formula (1): by reacting 3-buten-1-ol, a formaldehyde compound and formic acid, and (B) then, a solvolysis step of subjecting the tetrahydropyranyl-4-formate to solvolysis to obtain tetrahydropyran-4-ol represented by the formula (2): and an intermediate and a process for preparing the same.

Abstract: An inventive blue colorant comprising a chromophore having at least one hydroxy group-terminated polyester chain attached, through a suitable alkylamino linking group (or groups), to the 1-position, the 4-position, or both, of an anthraquinone backbone is provided. Such colorants exhibit excellent amine/base stability and thermal stability, effective colorations, excellent low extraction rates, and high lightfastness levels, particularly when incorporated within certain media and/or on the surface of certain polyurethane substrates. The polyester chain or chains can be conveniently tailored to increase the solubility or compatibility in different types of polyurethane resin precursors thereby permitting the introduction of such excellent coloring chromophores within diverse polyurethane media and/or or diverse polyurethane substrates as well as provides a liquid colorant which facilitates handling.

Abstract: Compounds, compositions and methods for treating degenerative diseases and disorders are disclosed, the compounds having the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein.

Abstract: Poly(propylene carbonates) are prepared from propylene oxide and CO2 with less than 10% cyclic propylene carbonate by product using cobalt based catalysts of structure preferably in combination with salt cocatalyst, very preferably cocatalyst where the cation is PPN+ and the anion is Cl? or OBzF5?. Novel products include poly(propylene carbonates) having a stereoregularity greater than 90% and/or a regioregularity of greater than 90%.

Abstract: Disclosed are colorant compounds of the formula wherein R, R1, R2, R3, and R4 each, independently of the others, is an alkyl group, an aryl group, an arylalkyl group, or an alkylaryl group, and wherein R, R1, R2, R3, and R4 each can be joined to a phenyl moiety to form a ring, each R?a, R?b, and R?c, independently of the others, is a halogen atom, an alkyl group, an alkoxy group, a nitrile group, a nitro group, an amide group, or a sulfonamide group, z1, z2, and z3 each, independently of the others, is an integer of 0, 1, 2, 3, or 4, n is an integer representing the number of carbon atoms in each repeat alkylene oxide unit, x is an integer representing the number of repeat alkylene oxide units, D is an anion, and g is the charge on the anion, wherein said colorant has no more than one —OH, —SH, or primary or secondary amino group per molecule.

Abstract: A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.

Abstract: The present invention provides a salt of the formula (I) wherein X represents —OH or —Y—OH, n shows an integer of 1 to 9, A+ represents an organic counter ion, Y represents a divalent saturated aliphatic hydrocarbon group having 1 to 6 carbon atoms. The present invention also provides a chemically amplified resist composition comprising the salt of the formula (I).

Abstract: It is an object of the present invention to provide a process for producing easily polymerizable substance, which can realize stable operation of a purification system, and can stably maintain a production amount by avoiding production stoppage, upon production of an easily polymerizable substance in plural reactors. The present invention is directed to a process for producing easily polymerizable substance, which comprises mixing easily polymerizable substances obtained in plural reactors in advance, and supplying the mixture to a purification apparatus.

Abstract: Described is a method for improving the spreading properties of fatty alcohol containing cosmetic ingredients by providing a fatty alcohol containing starting material and adding an effective amount of acylating source [e.g., R1C)?O)OC(?O)R2, where R1 is an alkyl substituent of the acyl group having between 1 and 5 carbons; where R2 is a long chain fatty alkyl subsistent (non-limiting examples are unsaturated substituents such as CH3—(CH2)7—CH?CH—CH2—(CH2)x—, and saturated substituents such as CH3—(CH2)y—, wherein x ranges from 4 to 12, and y ranges from 14 to 22, and the like)], wherein the spreading properties of the starting material are increased over the spreading properties originally exhibited.

Abstract: A process is provided for producing an enriched carboxylic acid compositions produced by contacting composition comprising a carboxylic acid with an enrichment feed in an enrichment zone to form an enriched carboxylic acid composition. This invention also relates to a process and the resulting compositions for removing catalyst from a carboxylic acid composition to produce a post catalyst removal composition.